Detail akcie PMV Pharma Rg online

Business Summary: PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, PMV Pharmaceuticals Inc revenues was not reported. Net loss increased 67% to $59.7M. Higher net loss reflects Research and development increase of 22% to $41.6M (expense), Interest income decrease of 39% to $5.1M (income), Labor & Related Expenses in R&D increase of 43% to $10.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.69 to -$1.14.